Could a simple pastille stop mouth cancer before it starts?
NCT ID NCT05865028
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether APG-157, a plant-based pastille taken three times daily, can shrink or eliminate precancerous growths in the mouth. Researchers will enroll 32 adults with moderate to severe oral dysplasia or carcinoma in situ. The goal is to see if the treatment reduces lesion size and improves tissue health over up to three 4-week cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APG-157 (a plant-based compound taken as a pastille)
- What this could lead to
- If it works, this could point toward a non-surgical treatment for precancerous mouth lesions, potentially preventing oral cancer.
- What could go wrong
- This is a small early-phase trial with only 32 people, so results may not apply broadly. The treatment may not shrink lesions or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.